LONDON, May 25, 2015 /PRNewswire/ -- Extra value: One
year of free online updates included with this product
There are today at least 995 protein kinase inhibitor drugs known
to affect more than 250 specific intracellular signaling pathways
for the treatment of more than 142 different tumor types. The
rational for this plethora of treatment strategies is based on our
increasing understanding of the 257 drug targets that are included
in this drug-pathway analyzing tool. No less than 252 of these have
been recorded with mutations and 51 drug targets have mutations
which have been causally implicated in cancer.
Pathway Coverage
- BioCarta# 228 Pathways
- KEGG# 166 Pathways
- NCI-Nature# 250 Pathways
- NetPath# 32 Pathways
Pipeline Coverage
Marketed# 34
Pre-registration# 8
Phase III# 62
Phase II# 216
Phase I# 284
Preclinical# 327
No Data# 13
Suspended# 5
Ceased# 353
The continuous identification of drug targets and pathways that are
altered in cancer is not only crucial for our understanding of
cancer biology, but also to search for new targets for early
diagnosis and improved treatment designs. Consequently, it has
never before been as important to rapidly translate systems biology
of disease and therapeutics to actionable pipeline decisions to
ensure that the optimal market conditions exist by the time a
candidate drug is commercialized.
For this reason BioSeeker, a leader in pipeline analytics, has
constructed this high-level drug-pathway analyzer which lets you
interact with the protein kinase inhibitor pipeline in a whole
different than way than you ever done before. Its capabilities
moves you beyond powerful competitive intelligence to an
opportunity seeking tool which lets you, by means of both present
and emerging scientific knowledge, analyze the protein kinase
inhibitor pipeline for interesting compounds which affect and/or
fit your purposes, may it be benchmarking, in/out-licensing,
combination therapy options, drug repositioning, indication
expansion etc.
You Use this Analyzer Tool of Protein Kinase Inhibitor Drugs
to:
* Map the competition and find suitable benchmarking/licensing
drugs based on specific pathways and drug properties
* Uncover potential indication expansion areas for your drug
portfolio
* Reveal repositioning opportunities for your older, shelved
drugs
* Evaluate the progression and success of targeting certain
pathways by different tumor types
* Investigate drugs which affect crosstalk between key pathways
* Investigate different combination therapy options available to
you in various cancer types. Use this tool to look for the
most-efficient ways to combine your drug with other targeted
agents.
* Find possible adjuvant therapy settings with other drugs.
This is how you do it:
In analyzing drug-pathway relationships this tool has three core
modes:
1. Select - You go right ahead and select any pathway for
analysis
2. Suggest - The tool can suggest pathways to you according to your
pipeline specifications
3. Compare - You can overlay any pathways with each other and do a
comparative analysis
You can interactively analyze any protein kinase inhibitor
drug-pathway relationship by using up to four different pathway
sources and further refine your analysis with up to 20 different
pipeline parameters, including parameters such as presence of
mutations, molecular function of targets, stage of development,
sub-cellular localization and many more. Each parameter has
multi-select options to them and can be used as either an inclusion
parameter or exclusion parameter.
User Reports with Graphics
Each analysis report generated in the Drug Pathway Analyzer
includes many different types of graphs and tables which can also
be easily downloaded and dropped into applications such as
PowerPoint for external presentations outside the tool.
The Pathway Analyzer Comes Integrated with Pipeline Information
With a simple click you can easily and quickly get relevant
information about the drug being included in a specific pathway. A
typical drug profile reports on, depending on stage of development
and available information:
Drug Name & Synonyms
Presentation of drug name and synonyms
Principal Company & Partners
Presentation of principal company and partners
Target and Molecular Function of Target
Described target(s) is/are presented with:
Official Gene Symbol – Chromosome Location – Gene & Protein
Name – Molecular Function
Target Localization
Described target(s) is/are presented with primary and alternate
localizations.
Target Expression Profiles
Links to protein expression profile(s) of target(s) in various
human tissues, cell lines and primary cells, including up to:
48 different normal tissue types
20 different types of cancer
47 cell lines
12 samples of primary blood cells
Mutation
All targets are cross-referenced with the Catalogue of Somatic
Mutations in Cancer (COSMIC). It is designed to store and display
somatic mutation information and related details and contains
information relating to human cancers.
Biological Structures
The identity of available biological structures on drug targets was
retrieved from the RCSB Protein Databank for you to easily review
what available structures of drug targets exist.
Targeted Pathways
Described target(s) is/are matched for the involvement in cellular
pathways according to BioCarta, KEGG, NCI-Nature and NetPath.
Mechanism
Drug mechanism of action
Developmental Projects
Summary field of developmental projects for the drug, including
indication, developmental stage and status.
Example:
Cancer, myeloma – Phase II Clinical Trial – Active
Cancer, prostate – Phase III Clinical Trial – Ceased
Drug Description
Short introduction to drug
Compound Data
Compound type, Chemical name, CAS Number and molecular weight
Patent Data
Available patent information related to the drug is presented
here.
Fillings and Approvals
Approvals and submissions
Analyst comments
Deals & Licensing
Collaborations and deals
Availability for licensing
Phase IV Data
Available Phase IV development data, developmental history and
scientific data.
Phase III Data
Available Phase III development data, developmental history and
scientific data.
Phase II Data
Available Phase II development data, developmental history and
scientific data.
Phase I Data
Available Phase I development data, developmental history and
scientific data.
Phase 0 Data
Available Phase 0 development data, developmental history and
scientific data.
Preclinical Data
Available preclinical development data, developmental history and
scientific data.
Discovery Data
Available discovery development data, developmental history and
scientific data.
System Requirements
- Operating system: Windows (2000/XP/Vista/7/8) and Mac Users are
offered Online Access Only
- Browser Application (Internet Explorer)
- Internet access (to access related internet resources)
Download the full report:
https://www.reportbuyer.com/product/2061668/
About Reportbuyer
Reportbuyer is a leading industry intelligence solution that
provides all market research reports from top publishers
http://www.reportbuyer.com
For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com
Tel: +44 208 816 85 48
Website: www.reportbuyer.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/protein-kinase-inhibitors-drug-pathway-analyzer-2015-300088269.html
SOURCE ReportBuyer